KR-20260064625-A - Detection structure, method of designing the same, and method of manufacturing the same

KR20260064625AKR 20260064625 AKR20260064625 AKR 20260064625AKR-20260064625-A

Abstract

A detection structure is provided comprising a fluorescent emitting material to which a biomarker is bound, and an amphiphilic polymer that self-assembles on the surface of the fluorescent emitting material to control the exposed surface of the fluorescent emitting material to which the biomarker is bound.

Inventors

조수연
이승주
류광희

Assignees

성균관대학교산학협력단
사회복지법인 삼성생명공익재단

Dates

Publication Date: 20260507
Application Date: 20251030
Priority Date: 20241030

Claims (15)

A fluorescent emitting substance to which a biomarker is bound; and A detection structure comprising an amphiphilic polymer that self-assembles on the surface of the fluorescent emitting material and controls the exposed surface of the fluorescent emitting material to which the biomarker is bound.
In Article 1, The above amphiphilic polymer covers the surface of the fluorescent emitting material to control the exposed surface, A detection structure comprising a surface coverage rate defined as the ratio of the amphiphilic polymer covering the surface of the fluorescent emitting material, wherein the surface coverage rate is controlled.
In Article 2, A detection structure comprising a surface coverage rate that is controlled to be greater than 38% and less than 95%.
In Article 1, A detection structure comprising the above-mentioned fluorescent emitting material having a binding energy that binds to the above-mentioned biomarker at a level greater than -25 kcal/mol and less than -12.5 kcal/mol.
A step of preparing a source solution by dissolving an amphiphilic polymer in a solvent; and A method for manufacturing a detection structure comprising the step of adding a fluorescent emitting material to the source solution to manufacture a detection structure in which the amphiphilic polymer is self-assembled on the surface of the fluorescent emitting material.
In Article 5, A method for manufacturing a detection structure, comprising the above-mentioned amphiphilic polymer having a molecular weight of more than 1,000 Da and less than 5,000 Da.
In Article 5, A method for manufacturing a detection structure, comprising the above-mentioned amphiphilic polymer forming a hydrophilic shell on the surface of the fluorescent emitting material through self-assembly.
In Article 7, A method for manufacturing a detection structure, wherein the above-mentioned hydrophilic shell provides biocompatibility and increases binding affinity with a biomarker.
In Article 5, A method for manufacturing a detection structure comprising adding the fluorescent emitting material to the source solution and dispersing it by ultrasound.
Step of selecting a fluorescent emitting material; A step of selecting candidate amphiphilic polymers for designing amphiphilic polymers that self-assemble on the surface of the above-mentioned fluorescent emitting material; and A method for designing a detection structure comprising the steps of designing factors of the candidate amphiphilic polymer that control the surface coverage rate, defined as the ratio of the amphiphilic polymer covering the surface of the fluorescent emitting material by self-assembly, and deriving the amphiphilic polymer.
In Article 10, A step of manufacturing a detection structure by self-assembling the amphiphilic polymer on the surface of the fluorescent emitting material; and A method for designing a detection structure, further comprising the step of providing a probe to the detection structure for quantifying the surface coverage rate of the fluorescent emitting material and measuring the surface coverage rate.
In Article 11, The above probe is selectively bound to the exposed surface of the fluorescent emitting material to quantify the surface coverage rate, and A method for designing a detection structure, wherein the above factor is designed according to the following equation. C 1 / △ = K d /q (Here, C1 is the concentration of the probe bound to the fluorescent substance, C2 is the concentration of the free probe, Δ is the difference between the total probe and the free probe concentrations, Kd is the dissociation constant (μM), which is the reciprocal of the binding affinity, and q is the maximum number of bond sites per carbon atom (mol/site))
In Article 12, The above factor is designed so that the difference in fluorescence spectra before and after the binding of the fluorescent emitting substance and the biomarker increases, and A method for designing a detection structure, comprising controlling the surface coverage rate to increase the biomarker bound to the surface of the fluorescent emitting material.
In Article 13, The above factor is, A method for designing a detection structure comprising the molecular weight, number of lipid carbons, number of double bonds, or terminal groups of the above-mentioned candidate amphiphilic polymer.
In Article 14, The above factor is, A method for designing a detection structure, comprising designing the K d /q value in the above formula to become smaller.

Description

Detection structure, method of designing the same, and method of manufacturing the same The present application relates to a detection structure, a method for designing the same, and a method for manufacturing the same. More specifically, it relates to a detection structure, a method for designing the same, and a method for manufacturing the same, wherein factors of a candidate amphiphilic polymer are designed through a method for designing a detection structure, a probe is provided to a detection structure manufactured from the amphiphilic polymer derived through the design, and quenching properties are measured to provide an optimal detection structure. In modern clinical practice, the rapid diagnosis of cerebrospinal fluid (CSF) leakage can be critical. With the increased prevalence of endoscopic transnasal skull base surgery and the rise in complex surgeries, the need to differentiate postoperative CSF leakage is on the rise. Accordingly, various techniques have been developed in the past for nasal skull base surgery. For example, Korean Registered Patent Publication No. 10-2213571 describes a surgical system for expanding the area of a patient's nasal sinus system, comprising a first sinus expansion device, wherein the first sinus expansion device comprises: a handle defining a front end opposite to a back end; a rigid probe extending distally from the front end of the handle, defining a proximal end at the front end of the handle, a distal tip opposite to the proximal end, and a curved segment between the proximal end and the distal tip; a balloon fixed to the rigid probe adjacent to the distal tip; an inflation path fluidly connected inside the balloon; a connector associated with the handle and configured to be electronically coupled to an image guidance system; and the first The system comprises an electronic identifier device programmed to generate a signal indicating an instrument identification corresponding to a zone of the patient's sinus system and assigned to a sinus dilator, wherein the curvature and longitudinal position of the curved arcuate are configured to position the balloon within one of the frontal sinus, maxillary sinus, and sphenoid sinus after insertion of the distal tip through the patient's naris, wherein the first sinus dilator is configured to access and process using the balloon, and the instrument identification is selected from a group consisting of a frontal sinus instrument, a maxillary sinus instrument, and a sphenoid sinus instrument, and the system further comprises a second sinus dilator, wherein the second sinus dilator comprises a handle, a rigid probe extending from the handle and forming a curved arcuate, a balloon fixed to the rigid probe adjacent to the distal tip and fluidly connected to an expansion path, a connector configured to be electronically coupled to the image guidance system, and an instrument electronically coupled to the connector and assigned to the second sinus dilator. A surgical system is disclosed comprising an electronic identifier device selected from a group consisting of a frontal sinus instrument, a maxillary sinus instrument, and a sphenoidal surgical instrument, which is programmed to generate a signal indicating identification, wherein the instrument identification of the first sinus expansion instrument is different from the procedure identification of the second sinus expansion instrument. However, commercially available non-invasive methods are practically non-existent to date, and invasive clinical methods such as endoscopic examination after injecting fluorescent dye into the spinal canal or computed tomography after injecting contrast agent are currently being utilized. Consequently, the current diagnosis of cerebrospinal fluid leakage may have limitations as it relies heavily on the subjective judgment of medical professionals. Accordingly, some research institutions are studying point-of-care (POC) diagnostic technologies based on specific biomarkers, such as lateral flow immunoassay (LFI) and immunochromatographic assay (ICA). While these technologies may offer the advantage of providing rapid results with relatively simple equipment, they may have limitations in terms of sensitivity and accuracy, and low accuracy can lead to false positives or false negatives. Furthermore, existing sensors may face limitations in sensitivity and selectivity in complex chemical environments where cerebrospinal fluid is mixed with nasal secretions. Although existing POC technologies recognize specific biomarkers using biological receptors, these receptors are synthesized in animal cells, which is time-consuming and costly, and they may also have limitations due to easy denaturation in unstable environments. In particular, the effectiveness of these biological receptors may be significantly reduced in complex chemical environments where cerebrospinal fluid is mixed with nasal secretions. Furthermore, as the related technology is currently at t